GTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.
- Mechanism
- Curator reviewed
GTI-2040 is an antisense drug that specifically targets the R2 component of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation. R2 has also been described as a malignant determinant that is elevated in a wide range of tumors, and through deregulation can cooperate with a variety of cellular cancer causing genes known as oncogenes to enhance tumor growth and metastatic potential.
- Primary indication
- Investigated for use/treatment in breast cancer, colorectal cancer, leukemia (myeloid), leukemia (unspecified), myelodysplastic syndrome, prostate cancer, renal cell carcinoma, and solid tumors.Curator reviewed
- Code names
- GTI 2040
Resolves to
What you can answer from here — as of April 23, 2025
Which drugs share a target with GTI 2040, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account